Sunday 01 October 2023 - 14:30
In Business 43 Years - Since 1980
NOTE: our usual phone and fax lines are down, due to a dispute between our landlord and Verizon.
In the meantime, please use this mobile phone number: 978-715-9327 and this fax number:
The 25% Discount for Shopping Cart Purchases is now PERMANENT !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
R-1234 Roscovitine, Free Base, >99%
Synonyms : [CYC202]
Related Terms : [Seliciclib]
- Size
- US $
- €
- £
- ¥
- 10 mg
- 49
- 46
- 40
- 7,300
- In stock
- 25 mg
- 67
- 63
- 54
- 10,000
- In stock
- 50 mg
- 128
- 120
- 104
- 19,100
- In stock
- 100 mg
- 169
- 159
- 138
- 25,200
- In stock
- 200 mg
- 224
- 211
- 183
- 33,500
- In stock
- 300 mg
- 294
- 277
- 241
- 43,900
- In stock
- 1 g
- 649
- 613
- 532
- 96,900
- In stock
- 2 g
- 1,110
- 1,048
- 910
- 165,800
- In stock
- 5 g
- 1,975
- 1,866
- 1,619
- 295,000
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 354.45
- C19H26N6O
- [186692-46-6]
- M.I. 14: 10240
Storage: Store at or below -20 ºC. Solubility: Prepare initial stock solutions in DMSO (soluble at 200 mg/mL) or ethanol (soluble at 200 mg/mL) for in vitro use; solubility in water is low. Appearance: White to off-white powder. Disposal: A.
- Roscovitine is a potent inhibitor of p34cdc2 (IC50 = 0.2 µM). Also inhibits p33cdk2 and p33cdk5. Havlicek, L., et al. "Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds." J. Med. Chem. 40: 408-412 (1997).
- NOTE: The word "Roscovitine" inherently means the R-isomer.
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
